Annals of Clinical and Experimental Neurology
https://annaly-nevrologii.com/journal/pathID
Annals of Clinical and Experimental Neurology | Pee-review medical journalResearch Center of Neurologyru-RUAnnals of Clinical and Experimental Neurology2075-5473<p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the Publisher right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International Licensee (<a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener">CC BY 4.0</a>) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See <a href="http://opcit.eprints.org/oacitation-biblio.html" target="_new">The Effect of Open Access</a>).</li> </ol> <p>All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Annals of Clinical and Experimental Neurology'.</p> <p>- DOWNLOAD the print-version of the License Agreement.</p> <div><details> <summary><strong>READ the details online</strong> (tap to see in details)</summary> <h4>Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Annals of Clinical and Experimental Neurology'</h4> <p><strong>License to use a Manuscript</strong></p> <p>The Author hereby grants Publisher of <em>Annals of Clinical and Experimental Neurology </em>journal (the ‘Journal’) a non-exclusive license to use, reproduce, distribute and publish the aforementioned Manuscript, metadata of the Manuscript and any other supplemental materials submitted as part of the Manuscript, including but not limited to tables, graphs, illustrations, research findings (the ‘Manuscript’) in any material form in print, electronic and all other media, in English, Russian and/or any other languages, with an unlimited number of copies, throughout the world, on an Open Access basis or by subscription, with no royalties, for the full term of the exclusive rights. The Publisher of the <em>Annals of Clinical and Experimental Neurology </em>journal is Research Center of Neurology.</p> <p><strong>Terms of publication</strong></p> <p>The Author has reviewed and hereby accepts the following terms of publication:</p> <ol> <li>The Editorial Board of the Journal are guided by the norms developed by the Committee on Publication Ethics (COPE) and the norms, specified in the Declaration of the Association of Scientific Editors and Publishers ‘Ethical Principles of Scientific Publications’.</li> <li>The publication of Manuscripts in <em>Annals of Clinical and Experimental Neurology</em> is free of charge.</li> <li>The Manuscript submitted to the Journal for publication has not been previously published and/or is not under consideration by any other journal or periodical.</li> <li>The Manuscript submitted to the Journal has been prepared in compliance with the Acceptance and Publication Rules of the Journal (the ‘Rules’). The Rules are available at <a href="https://annaly-nevrologii.com/">https://annaly-nevrologii.com/</a> </li> <li>All Manuscripts submitted to the Journal are peer reviewed.</li> <li>The editorial staff of the Journal is entitled to carry out technical, scientific and literary editing of the Manuscript so that its content remains unchanged. All changes relating to the scientific component of the Manuscript and/or its content are to be agreed with the Author. </li> <li>The editorial staff represented by the Editor-in-chief and/or Editorial Executive Board of the Journal have the right not to accept the Manuscript for publication in cases, including but not limited to the Manuscript not corresponding to the topics covered by the Journal or any part of it, or if the submitted materials are deemed insufficient for a separate publication, the design of the Manuscript does not correspond to the rules of the Journal, the norms of publication ethics have been violated by the Author or if illegal borrowings or duplicate publications have been revealed. </li> <li>The Manuscript is accepted for publication by the Editor-in-chief, following the recommendations of the reviewer and the Editorial Board.</li> <li>The Manuscript accepted for publication will be published in the Journal in accordance with the terms of the Creative Commons Attribution 4.0 International license (СС-BY). The CC-BY license allows users to copy and distribute materials in all forms and across all media, and to create materials derived from the original material for any purposes, including for commercial purposes. The full details of the CC-BY license are available at: <a href="https://creativecommons.org/licenses/by/4.0/legalcode">https://creativecommons.org/licenses/by/4.0/legalcode</a></li> <li>After the Manuscript has been published in the Journal the Author has the right to publish the Manuscript in other periodicals. The Author shall indicate that the Manuscript was first published in the Journal with obligatory reference to the number, month, year of publication and link to the formal publication (through the relevant DOI).</li> </ol> <p><strong>Guarantees of the Author</strong></p> <p>The Author guarantees that:</p> <ol> <li>he/she is the legitimate copyright holder of the article; the rights granted to the Journal under this Agreement have not been transferred and will not be transferred to third parties before the publication of the Manuscript in the Journal;</li> <li>the Manuscript contains all the references to cited authors and/or sources (materials) in accordance with the copyright law of the Russian Federation and/or legislation of the country of the Author’s citizenship (residence);</li> <li>the Author has received all the required licenses (permissions) to use results, facts and other borrowed content in the article, should the Author not be the copyright holder;</li> <li>at the time of submission of the Manuscript to the Journal, the rights to use the Manuscript will not have been transferred to third parties and the Manuscript will not have been published in any other journal and/or periodical;</li> <li>the Manuscript does not contain materials which are not liable for publication in open sources, in line with the normative legal acts of the Russian Federation or any other country of the Author’s citizenship (residence) and the publication and distribution of the article will not lead to the disclosure of secret (confidential) information, including state secrets;</li> <li>the Author has obtained all consents in accordance with the legislation of the Russian Federation and/or the country of the Author’s citizenship (residence) in terms of the use of personal data and/or images of patients, research subjects and other persons;</li> <li>the Author has informed the co-authors of the terms of this Agreement and obtained consents from all co-authors to sign this Agreement according to the specified conditions.</li> </ol> <p><strong>Other conditions</strong></p> <ol> <li>The interaction, correspondence and transmission of materials and information is permitted by any communication method, available to both the Author and the Journal, with priority given to the online management editorial system on the Journal website and, including but not limited to, postal items, courier services, express delivery services, email and instant messaging systems (client programmes for online messaging). The scanned copies of original documents, transmitted by means of the aforementioned communication methods, are effective as originals for all Parties until the originals are exchanged.</li> <li>This Agreement shall be construed in accordance with the legislation of the Russian Federation. All disputes that may arise under this Agreement shall be settled in accordance with the standard business practices and legislation of the Russian Federation.</li> </ol> <p><strong>Registered Address and Particulars of the Publisher</strong></p> <p>Research Center of Neurology</p> <p>Address: 80, Volokolamskoye shosse, Moscow, 125367</p> <p>WEB: <a href="http://www.neurology.ru/" target="_blank" rel="noopener">http://www.neurology.ru</a></p> <p>E-mail: <a href="mailto:center@neurology.ru">center@neurology.ru</a> </p> <p>Phone: +7 (495) 374-77-76</p> </details></div>The Long-Term Course of Chronic Inflammatory Demyelinating Polyneuropathy: a Retrospective Study
https://annaly-nevrologii.com/journal/pathID/article/view/1002
<p><strong>Introduction<em>.</em></strong> Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by long-term progressive or relapsing course, neurological deficit, and disability of varied severity. The course of CIDP after specific therapy and, if necessary, long-term maintenance treatment are to be studied.</p> <p><strong>Objective<em>:</em></strong> To evaluate CIDP clinical and history characteristics over the long-term follow-up (> 5 years), to compare long-term CIDP course in a number of clinical variants and onset types, and to determine clinical predictors of unfavorable CIDP course.</p> <p><strong>Materials and methods<em>.</em></strong> The study included 45 patients diagnosed with CIDP based on EAN/PNS 2021 criteria lasting for 5 or more years. Retrospective collection and analysis of medical records and clinical history were performed. Internationally accepted scales were used to assess neurological deficit (NIS, MRCss), disability (INCAT), and disease activity status (CDAS). The criteria of unfavorable course were developed to evaluate factors affecting CIDP course.</p> <p><strong>Results<em>.</em></strong> Among the patients with CIDP history of >5 years, each third (34%) had no neurological deficit and remained in long-term clinical remission (CDAS 1). The vast majority (90%) responded to first-line therapy in early disease, while only 53% of patients required maintenance treatment in 5 or more years of the onset. With the developed criteria (poor response to glucocorticosteroids (GCS), need for maintenance therapy, and CDAS 3–5), unfavourable CIDP course was detected in 24 (53.3%) participants. Its probability increased in later onset (47 [30; 50] years), the chronic type of onset, and delayed specific therapy. The most significant predictors included low total NIS score at onset (<60 points) and multifocal CIDP.</p> <p><strong>Conclusions<em>.</em></strong> The course of typical CIDP is relatively favorable if timely diagnosed, and pathogenetic treatment initiated. Patients with acute and subacute onset demonstrate the best long-term status. The predictors of unfavourable disease course include mild neurological deficit at onset (NIS total score <60 points) and multifocal CIDP.</p>Evgeniya A. MelnikAlina S. ArestovaIrina A. BerdalinaElena V. GnedovskayaDarya A. GrishinаNatalia A. SuponevaMichail A. Piradov
Copyright (c) 2023 Melnik E.A., Arestova A.S., Berdalina I.A., Gnedovskaya E.V., Grishinа D.A., Suponeva N.A., Piradov M.A.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-2517451610.54101/ACEN.2023.4.1Mood Disorders After COVID-19
https://annaly-nevrologii.com/journal/pathID/article/view/886
<p><strong>Introduction<em>.</em></strong> The COVID-19 pandemic has led to a high prevalence of post-COVID-19 syndrome (PCS), with mood disorders being the most common manifestations.</p> <p><strong>Objective<em>:</em></strong> To study the prevalence of PCS-associated mood disorders and their features.</p> <p><strong>Materials and methods<em>.</em></strong> We examined patients after COVID-19 (n = 91; age: 24-84 years; median time to recovery: 7 months) using the following tools: the BDI and HADS (screening for anxiety and depression); the Starkstein Apathy Scale; FIS and FSS (fatigue assessment); the MoCA, MMSE, and FAB (cognitive assessment); the FIRST, ESS, PSQI, and ISI (sleep disorders evaluation); the EQ5D (quality of life measurement). We designed a special questionnaire to collect data related to a history of COVID-19 and patients' condition after discharge. In addition, we analyzed electronic medical records and discharge summaries and performed neurological examination.</p> <p><strong>Results<em>.</em></strong> Of all the examined patients, 65 (71.4%) participants had signs and symptoms of PCS. Mood disorders were observed in 33 (50.8%) cases, with apathy (78.7%), anxiety (66.7%), and fatigue (60.6%) being the most common. Depressive disorders were found in 12 (36.3%) patients. Cognitive functions were impaired in 7 (21.2%) patients; sleep disorders were observed in 16 (48.5%) cases. We found a positive correlation between depressive disorders and fatigue based on the BDI, FIS, and FSS scores (rS = 0.711; rS = 0.453), depressive disorders and anxiety (rS = 0.366), fatigue and apathy (rS = 0.350). Anxiety increased the risk of sleep disorders (rS = 0.683). Quality of life has been shown to decrease in patients with mood disorders due to the negative effect of long-term fatigue and depressive disorders.</p> <p><strong>Conclusions<em>.</em></strong> There is a close connection between different types of mood disorders that develop after COVID-19 and exacerbate symptoms of each other. Early diagnosis and treatment of these disorders can improve patients' quality of life and preserve their ability to work.</p>Anna G. MikheevaMariya P. TopuzovaValeriya A. MalkoEkaterina S. ZhilinaArina A. MikhailovaDaria I. LagutinaTatiana L. KaronovaTatyana M. Alekseeva
Copyright (c) 2023 Mikheeva A.G., Topuzova M.P., Malko V.A., Zhilina E.S., Mikhailova A.A., Lagutina D.I., Karonova T.L., Alekseeva T.M.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174172710.54101/ACEN.2023.4.2MRI-Guided Focused Ultrasound in Cervical Dystonia
https://annaly-nevrologii.com/journal/pathID/article/view/1020
<p><strong>Introduction<em>.</em></strong> MRI-guided focused ultrasound (MRgFUS) is approved for management of various movement disorders, primarily essential tremor and Parkinson’s disease (PD), with favorable long-term outcomes in numerous patients worldwide. However, few case studies describe the use of this modality for symptomatic treatment of dystonias that, as the third most common movement disorder, may be rather disabling.</p> <p><strong>Objective<em>:</em></strong> To improve outcomes in patients with cervical dystonia (CD) using MRgFUS.</p> <p><strong>Materials and methods<em>. </em></strong>We retrospectively analyzed 13 cases of various CD types managed with MRgFUS in single or multiple sessions. The mean age of the patients was 42 [39; 53] years. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) was used to assess patients' statuses and severity of CD symptoms during therapy and the last available observation period. The targets included the pallidothalamic tract and the thalamic ventral oralis complex nucleus or their combination.</p> <p><strong>Results<em>.</em></strong> The mean follow-up period was 13.3 ± 3.4 months (July 2021 to April 2023). The mean CD severity sum score (TWSTRS score) was 22 [16; 25] before MRgFUS and 6 [4; 9] in the last observation. Therefore, we report 70.6% [55.6; 76.5] improvement (paired samples t-test p = 0.0025).</p> <p><strong>Conclusion<em>.</em></strong> Available data evidence that MRgFUS is efficient and sufficiently safe for symptomatic treatment in pharmacoresistant CD patients. A number of vital aspects of MRgFUS have to be specified in larger CD cohorts in the long-term follow-up.</p>Rezida M. GalimovaSergey N. IllarioshkinIgor V. BuzaevYulia A. SidorovaDmitriy K. KrekotinShamil M. SafinDinara I. NabiullinaGulnara N. AkhmadeevaDinara R. Teregulova
Copyright (c) 2023 Galimova R.M., Illarioshkin S.N., Buzaev I.V., Sidorova Y.A., Krekotin D.K., Safin S.M., Nabiullina D.I., Akhmadeeva G.N., Teregulova D.R.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174283410.54101/ACEN.2023.4.3Long-Term Outcomes of Management of Inferior Alveolar Neuropathy Following Orthognatic Surgeries in Patients with Mandibular Anomalies and Deformities
https://annaly-nevrologii.com/journal/pathID/article/view/1009
<p><strong>Introduction<em>.</em></strong> Orthognatic surgery is a routine method to manage mandibular anomalies and deformities.</p> <p><strong>Objective<em>:</em></strong> To assess long-term outcomes of rhythmic peripheral magnetic stimulation (rPMS) in patients with neuropathy of the inferior alveolar nerve (IAN) resulting from the surgical treatment of mandibular anomalies and deformities.</p> <p><strong>Materials and methods<em>. </em></strong>The study included 8 males and 16 females aged 32 ± 12 years with IAN neuropathy following the surgical treatment of mandibular anomalies and deformities. Therapeutic rPMS was performed with the Neuro-MS magnetic stimulator (Neurosoft, Ivanovo, Ivanovo Region, Russian Federation). Trigeminal and brainstem acoustic evoked potentials (EPs) were registered with Neuro-MVP (Neurosoft) to assess rPMS both at baseline (in 10 days) and in long term (in 18 ± 2 months).</p> <p><strong>Results<em>.</em></strong> Sensory disorders and pain prevailed in postoperative IAN neuropathy. Sensory disorders improved in 20 patients following 10-day rPMS. The clinical effect persisted in re-assessment. In long term, acoustic brainstem EPs normalized and trigeminal EPs did not change negatively.</p> <p><strong>Conclusion<em>.</em></strong> The use of rPMS in IAN neuropathy following orthognatic surgeries contributes to the functional improvement and stabilization of the peripheral and central brainstem and the trigeminal system.</p>Marine M. TanashyanMarina Yu. MaximovaPavel A. FedinTatiana Yu. Noskova
Copyright (c) 2023 Tanashyan M.M., Maximova M.Y., Fedin P.A., Noskova T.Y.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174353910.54101/ACEN.2023.4.4Long-term Intracerebroventricular Administration of Ouabain Causes Motor Impairments in C57Bl/6 Mice
https://annaly-nevrologii.com/journal/pathID/article/view/978
<p><strong>Introduction<em>.</em></strong> Cardiac glycosides are natural ligands of Na<sup>+</sup>/K<sup>+</sup>-ATPase, which regulate its activity and signaling. Intracerebroventricular administration of ouabain has been previously shown to induce hyperlocomotion in C57Bl/6 mice via a decrease in the rate of dopamine reuptake from the synaptic cleft.</p> <p><strong>Materials and methods<em>.</em></strong> This study involved forty C57BL/6 mice. 1.5 μL of 50 μM ouabain was administered daily into the left lateral cerebral ventricle over the course of 4 days. On day 5, open field, beam balance, and ladder rung walking tests were performed to assess the locomotor activity and motor impairments in the mice. We evaluated changes in the activation of signaling cascades, ratios of proapoptotic and antiapoptotic proteins, and the amount of α1 and α3 isoforms of the Na<sup>+</sup>/K<sup>+</sup>-ATPase α-subunit in brain tissue using Western blotting. Na<sup>+</sup>/K<sup>+</sup>-ATPase activity was evaluated in the crude synaptosomal fractions of the brain tissues.</p> <p><strong>Results<em>.</em></strong> We observed hyperlocomotion and stereotypic behavior during the open field test 24 hours after the last injection of ouabain. On day 5, the completion time and the number of errors made in the beam balance and ladder rung walking tests increased in the mice that received ouabain. Akt kinase activity decreased in the striatum, whereas the ratio of proapoptotic and antiapoptotic proteins and the number of Na<sup>+</sup>/K<sup>+</sup>-ATPase α-subunits did not change. Na<sup>+</sup>/K<sup>+</sup>-ATPase activity increased in the striatum and decreased in the brainstem.</p> <p><strong>Conclusions<em>.</em></strong> Long-term exposure to ouabain causes motor impairments mediated by changes in the activation of signaling cascades in dopaminergic neurons.</p>Yulia A. TimoshinaRogneda B. KazanskayaVladislav A. ZavialovAnna B. VolnovaAlexander V. LatanovTatiana N. FedorovaRaul R. GainetdinovAlexander V. Lopachev
Copyright (c) 2023 Timoshina Y.A., Kazanskaya R.B., Zavialov V.A., Volnova A.B., Latanov A.V., Fedorova T.N., Gainetdinov R.R., Lopachev A.V.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174405110.54101/ACEN.2023.4.5Copper Ions Reduced Toxicity of Sodium Azide and Lipopolysaccharide on Cultured Cerebellar Granule Neurons
https://annaly-nevrologii.com/journal/pathID/article/view/986
<p><strong>Introduction<em>.</em></strong> Copper ions (Cu<sup>2+</sup>) are structural elements of proteins such as cytochrome с oxidase (Complex IV), an enzyme that catalyzes the final step of electron transfer to oxygen during oxidative phosphorylation in the mitochondria. With Cu<sup>2+</sup> homeostasis being of utmost importance, its disturbances in the central nervous system are involved in the mechanisms of many neurodegenerative and other brain disorders.</p> <p><strong>This study aimed</strong> to assess the effects of non-toxic copper ion levels on death of cerebellar granule neurons associated with lipopolysaccharide (LPS; in vitro inflammation model) or azide sodium (NaN3; cytochrome с oxidase inhibitor).</p> <p><strong>Materials and methods<em>.</em></strong> LPS (10 μg/mL) or NaN3 (250 μM) was added on day 7 to 8 to the culture medium with rat cerebellar cells for 24 hours in vitro. Nitrite concentrations were measured in the culture medium by Griess assay; absorbance was recorded with a spectrophotometer at 540 nm, and morphologically intact cells were counted as survived neurons.</p> <p><strong>Results<em>.</em></strong> Added to the culture medium, LPS or NaN3 reduced neuron survival to 15 ± 2% or 20 ± 3% vs. control, respectively. Cu<sup>2+</sup> (0.5 to 5.0 μM) increased neuron survival in a dose-dependent manner to 78 ± 4% with toxic levels of LPS and to 86 ± 6% with NaN3 with 5 μM Cu<sup>2+</sup>. The concentration of nitrites in the control culture medium was 2.0 ± 0.2 μM. Added to the cell cultures, LPS increased the concentration of nitrites to 8.5 ± 0.5 μM. Cu<sup>2+</sup> 5 μM did not show any significant effects on nitrite accumulation in the culture medium.</p> <p><strong>Conclusions<em>.</em></strong> We showed that copper ions can exert protective effects on neurons against LPS-induced or NaN<sub>3</sub>-induced toxicity. This protection is likely to be associated rather with Cu<sup>2+</sup> interaction with Complex IV of the electron transfer chain in the mitochondria than with inhibition of NO production. Effects of Cu<sup>2+ </sup>on apoptosis pathway proteins also cannot be ruled out.</p>Elena V. StelmashookOlga P. AlexandrovaElizaveta E. GenrikhsYeshvandra VermaAlla B. SalminaNickolay K. Isaev
Copyright (c) 2023 Stelmashook E.V., Alexandrova O.P., Genrikhs E.E., Verma Y., Salmina A.B., Isaev N.K.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174525710.54101/ACEN.2023.4.6Assessment of Mitochondrial Gene Activity in Dopaminergic Neuron Cultures Derived from Induced Pluripotent Stem Cells Obtained from Parkinson's Disease Patients
https://annaly-nevrologii.com/journal/pathID/article/view/1045
<p><strong>Introduction<em>.</em></strong> Induced pluripotent stem cells (iPSCs) culturing allows modelling of neurodegenerative diseases in vitro and discovering its early biomarkers.</p> <p>Our<strong><em> </em></strong><strong>objective<em> </em></strong>was to evaluate the activity of genes involved in mitochondrial dynamics and functions in genetic forms of Parkinson's disease (PD) using cultures of dopaminergic neurons derived from iPSCs.</p> <p><strong>Materials and methods<em>.</em></strong> Dopaminergic neuron cultures were derived by reprogramming of the cells obtained from PD patients with SNCA and LRRK2 gene mutations, as well as from a healthy donor for control. Expression levels of 112 genes regulating mitochondrial structure, dynamics, and functions were assessed by multiplex gene expression profiling using NanoString nCounter custom mitochondrial gene expression panel.</p> <p><strong>Results<em>.</em></strong> When comparing the characteristics of the neurons from patients with genetic forms of PD to those of the control, we observed variations in the gene activity associated with the mitochondrial respiratory chain, the tricarboxylic acid cycle enzyme activities, biosynthesis of amino acids, oxidation of fatty acids, steroid metabolism, calcium homeostasis, and free radical quenching. Several genes in the cell cultures with SNCA and LRRK2 gene mutations exhibited differential expression. Moreover, these genes regulate mitophagy, mitochondrial DNA synthesis, redox reactions, cellular detoxification, apoptosis, as well as metabolism of proteins and nucleotides.</p> <p><strong>Conclusions<em>.</em></strong> The changes in gene network expression found in this pilot study confirm the role of disrupted mitochondrial homeostasis in the molecular pathogenesis of PD. These findings may contribute to the development of biomarkers and to the search for new therapeutic targets for the treatment of SNCA- and LRRK2-associated forms of the disease.</p>Anna S. VetchinovaMarina R. KapkaevaNatalia M. MudzhiriSergey N. Illarioshkin
Copyright (c) 2023 Vetchinova A.S., Kapkaeva M.R., Mudzhiri N.M., Illarioshkin S.N.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174586310.54101/ACEN.2023.4.7Poststroke Asthenic Disorder
https://annaly-nevrologii.com/journal/pathID/article/view/882
<p>Asthenic disorders are seen in approximately half of poststroke patients. The mechanisms underlying poststroke asthenia (PSA) are related to brain connectome damage, as well as neuroinflammatory and neuroendocrine mechanisms. PSA is associated with a lack of energy, lassitude, and fatigue that do not improve after rest or sleep; it is differentiated from depression, apathy, and daytime drowsiness. Risk factors for PSA include female gender, anxiety and depressive disorders, severe neurological deficit, sleep disorders, diabetes etc. Treatment of PSA includes cognitive behavioral therapy graded physical activity, and pharmacotherapy.</p>Mansur A. KutlubaevAlbina I. Akhmetova
Copyright (c) 2023 Kutlubaev M.A., Akhmetova A.I.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174647110.54101/ACEN.2023.4.8Neurobehavioral Testing as Cognitive Function Evaluation tool in Experimentally Induced Neurodegeneration in Mice
https://annaly-nevrologii.com/journal/pathID/article/view/868
<p>Neurodegeneration is a complex and multifactorial process presenting one of the major issues of fundamental science and clinical medicine due to its high prevalence, multiple nosological entities, and variations in pathogenesis. Translational research contributes to the study of neurodegenerative diseases, with modeling of such pathologies being an important part of this research. Behavioral testing in various animal models of neurodegenerative diseases allows to assess the model validity and reliability, as well as to investigate the potential efficacy of pharmacotherapy and other management approaches. In this overview we present test batteries that evaluate behavior, cognitive performance, and emotional states in animals with experimentally induced neurodegeneration.</p>Yulia A. PaninaOlga L. LopatinaAngelina I. MosyaginaYulia K. KomlevaAndrey V. MorgunYana V. GorinaElena D. Hilazheva
Copyright (c) 2023 Panina Y.A., Lopatina O.L., Mosyagina A.I., Komleva Y.K., Morgun A.V., Gorina Y.V., Hilazheva E.D.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174728110.54101/ACEN.2023.4.9Brain–Computer Interface Using Functional Near-Infrared Spectroscopy for Post-Stroke Motor Rehabilitation: Case Series
https://annaly-nevrologii.com/journal/pathID/article/view/953
<p><strong>Introduction<em>.</em></strong> Non-invasive brain–computer interfaces (BCIs) enable feedback motor imagery [MI] training in neurological patients to support their motor rehabilitation. Nowadays, the use of BCIs based on functional near-infrared spectroscopy (fNIRS) for motor rehabilitation is yet to be investigated.</p> <p><strong>Objective<em>:</em></strong> To evaluate the potential fNIRS BCI use in hand MI training for comprehensive post-stroke rehabilitation.</p> <p><strong>Materials and methods<em>.</em></strong> This pilot study included clinically stable patients with mild-to-moderate post-stroke hand paresis. In addition to the standard rehabilitation, the patients underwent 10 nine-minute MI fNIRS BCI training sessions. To evaluate the quality of fNIRS BCI control, we assessed the percentage of time during which the classifier accurately detected patient's mental state. We scored the hand function using the Action Research Arm Test (ARAT) and the Fugl-Meyer Assessment (FMA).</p> <p><strong>Results<em>.</em></strong> The study included 5 patients at 1 day to 12 months of stroke. All the participants completed the study. All study participants achieved BCI control rates higher than random (41–68%). While three patients demonstrated the clinically significant improvements in their ARAT scores, one of them also showed an improvement in the FMA score. All the participants reported experiencing drowsiness during training.</p> <p><strong>Conclusions<em>.</em></strong> Post-stroke patients can operate the fNIRS BCI system under investigation. We suggest adjusting the feedback system, extending the duration of training, and incorporating functional electromyostimulation to enhance training effectiveness.</p>Roman Kh. LyukmanovMikhail R. IsaevOlesya A. MokienkoPavel D. BobrovEkaterina S. IkonnikovaAnastasiia N. CherkasovaNatalia A. Suponeva
Copyright (c) 2023 Lyukmanov R.K., Isaev M.R., Mokienko O.A., Bobrov P.D., Ikonnikova E.S., Cherkasova A.N., Suponeva N.A.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174828810.54101/ACEN.2023.4.10Relapsing Autoimmune GFAP Astrocytopathy: Case Report
https://annaly-nevrologii.com/journal/pathID/article/view/939
<p><strong>Introduction<em>.</em></strong> Glial fibrillary acidic protein (GFAP) is the main component of intermediate astrocyte filaments. In 2016, anti-GFAP antibodies (Ab) were identified as the specific biomarker for the first established CNS inflammatory disorder subsequently called autoimmune astrocytopathy associated with anti-GFAP Ab (A-GFAP-A). Since GFAP is localized intracellularly, GFAP Ab do not appear to be directly pathogenic though serve as a biomarker of immune inflammation. Although presence of GFAP-Ab in the serum (but not in the CSF) could be observed in various CNS immune-mediated diseases, detection of GFAP-Ab in CSF is only characteristic for A-GFAP-A. A-GFAP-A usually develops after the age of 40 and mostly manifests acutely or subacutely with symptoms of meningoencephalomyelitis or its focal forms. Linear perivascular radial cerebral white matter enhancement is a specific MRI finding of A-GFAP-A. Concomitant neoplasms or autoimmune disorders, as well as co-expression of other antineuronal antibodies are not uncommon in A-GFAP-A. Usually, disease responds well to immunotherapy, and prolonged remission could be achieved, however recurrent disease course and fulminant cases are also described in the literature. In these cases, long-term immunosuppression is required. Data on epidemiology, etiological factors, and precise pathogenesis of A-GFAP-A are still limited. Due to the lack of long-term follow-up data, diagnostic criteria, generally accepted treatment strategies or prognostic risk factors for relapse and outcome of the disease have not yet been established and precised. We present the first description of a case of relapsing A-GFAP-A in Russia and an analysis of the current data on the pathogenesis, clinical features, as well as the diagnostic challenges and treatment approaches for A-GFAP-A.</p>Ekaterina O. ChekanovaАlla А. ShabalinaTaras O. SimanivRodion N. KonovalovLarisa A. DobryninaLyudmila A. KalashnikovaMaria V. GubanovaMaria N. Zakharova
Copyright (c) 2023 Chekanova E.O., Shabalina А.А., Simaniv T.O., Konovalov R.N., Dobrynina L.A., Kalashnikova L.A., Gubanova M.V., Zakharova M.N.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-25174899610.54101/ACEN.2023.4.11A Clinical Case of Corticospinal Tract Reorganization of Supplementary Motor Area in a Child After Acute Hypoxic Brain Injury
https://annaly-nevrologii.com/journal/pathID/article/view/947
<p>We present clinical observation of a 3-year-old child during recovery after acute hypoxic brain injury (freshwater drowning). Using diagnostic transcranial magnetic stimulation and magnetic resonance tractography with reconstruction of the corticospinal tract (CST) originated from the primary motor cortex and supplementary motor area (SMA), we determined that hypoxic brain injury induced activation of CST from the SMA. The period of reorganization was associated with the development of epileptiform patterns, that confirms the transient hyperexcitability of cortical neurons. Our findings indicate no recovery of motor function after acute hypoxic brain injury when CST originated only from SMA.</p>Daria S. KanshinaIlya A. MelnikovMaksim V. UblinskySergey S. NikitinSvetlana A. ValliulinaTolibdzhon A. AkhadovMaria A. Surma
Copyright (c) 2023 Kanshina D.S., Melnikov I.A., Ublinsky M.V., Nikitin S.S., Valliulina S.A., Akhadov T.A., Surma M.A.
https://creativecommons.org/licenses/by/4.0
2023-12-252023-12-251749710110.54101/ACEN.2023.4.12